IMMUNOGENECITY OF NP-ISS COMBINED WITH INFLUENZA VIRUS VACCINE

NP-ISS 与流感病毒疫苗联用的免疫原性

• 批准号: 7349802
• 负责人: KATHLEEN M BRASKY
• 金额: $ 2.3万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349802
• 关键词: IMMUNOGENECITY; NP; ISS; COMBINED; INFLUENZA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prevnar¿ is a vaccine for infants and children that helps prevent certain invasive pneumococcal disease caused by streptococcus pneumonia, which can cause life-threatening meningitis and blood infections. The objective of this experiment is to assess whether Prevnar¿ + ISS vaccine formulations enhance the immunogenicity in adult baboons of the Prevnar¿ licensed pneumococcal vaccine. This experiment will help determine if the addition of ISS can enhance the immune response to a pneumococcal polysaccharide antigen vaccine. The pneumococcal vaccine has yearly manufacturing shortages that require physicians to reduce pediatric immunization recommendations - babies don¿t end up getting all the doses of vaccine they are supposed to, and are therefore not optimally protected. ISS enhanced immunologic responses may allow use of a lower antigen dose, thereby reducing yearly vaccine shortages and enhancing infant health. This new pneumococcal vaccine (Prevnar + ISS) may be beneficial to society since it could improve responses to pneumococcal antigens in infants.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。Prevnar是一种婴儿和儿童疫苗，有助于预防由肺炎链球菌引起的某些侵袭性肺炎球菌疾病，这种疾病可能导致危及生命的脑膜炎和血液感染。本实验的目的是评估Prevnar+ISS疫苗配方是否能增强Prevnar许可肺炎球菌疫苗对成年狒狒的免疫原性。这项实验将有助于确定添加ISS是否可以增强肺炎球菌多糖类抗原疫苗的免疫反应。肺炎球菌疫苗每年都会出现生产短缺，这要求医生减少儿科免疫建议--婴儿最终没有得到他们应该接种的所有剂量的疫苗，因此没有得到最佳保护。ISS增强的免疫反应可能允许使用较低的抗原剂量，从而减少每年的疫苗短缺，并增强婴儿健康。这种新型肺炎球菌疫苗(Prevnar+ISS)可能对社会有益，因为它可以改善婴儿对肺炎球菌抗原的反应。